0001104659-22-114206.txt : 20221103 0001104659-22-114206.hdr.sgml : 20221103 20221103071216 ACCESSION NUMBER: 0001104659-22-114206 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20221101 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221103 DATE AS OF CHANGE: 20221103 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cara Therapeutics, Inc. CENTRAL INDEX KEY: 0001346830 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36279 FILM NUMBER: 221356185 BUSINESS ADDRESS: STREET 1: 4 STAMFORD PLAZA STREET 2: 107 ELM STREET 9TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06902 BUSINESS PHONE: 203-406-3700 MAIL ADDRESS: STREET 1: 4 STAMFORD PLAZA STREET 2: 107 ELM STREET 9TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06902 FORMER COMPANY: FORMER CONFORMED NAME: Cara Therapeutics Inc DATE OF NAME CHANGE: 20051213 8-K 1 tm2229601d1_8k.htm FORM 8-K
0001346830 false 0001346830 2022-11-01 2022-11-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) November 1, 2022

  

CARA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-36279   75-3175693

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

         

4 Stamford Plaza

107 Elm Street, 9th Floor

Stamford, Connecticut

       06902
 (Address of principal executive
offices)		       (Zip Code)
         
Registrant's telephone number, including area code (203) 406-3700

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

  

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol Name of each exchange on which
registered
Common Stock, par value $0.001 per share CARA The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

   

 

 

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.

 

On November 1, 2022, the Board of Directors (the “Board”) of Cara Therapeutics, Inc. (the “Company”) appointed Lisa von Moltke, M.D. to serve as a member of the Board with a term expiring at the Company’s 2023 Annual Meeting of Stockholders. Dr. von Moltke was appointed to serve as a member of the nominating and corporate governance committee of the Board. There is no arrangement or understanding between Dr. von Moltke and any other person pursuant to which she was selected as a director, and there is no family relationship between Dr. von Moltke and any of the Company’s other directors or executive officers.

 

Dr. von Moltke, age 63, currently serves as Executive Vice President and Chief Medical Officer at Seres Therapeutics, Inc. (“Seres”), a position she has held since April 2020. Prior to joining Seres, Dr. von Moltke served in roles of increasing seniority at Alkermes, Inc. from June 2015 to December 2019, culminating as Senior Vice President and Head of Clinical Development. Dr. von Moltke has served as President of the American College of Clinical Pharmacology and Editor-in-Chief of The Journal of Clinical Pharmacology. She received a B.A. from Wellesley College and M.D. from Michigan State University, College of Human Medicine.

 

In accordance with the Company’s non-employee director compensation policy, Dr. von Moltke will receive an annual cash retainer of $45,000 for her service as a director, an annual cash retainer of $5,000 for her service on the nominating and corporate governance committee and, on January 2, 2023, an initial stock option grant with a Black-Scholes value of $350,000. This option will vest over a period of three years, in twelve equal quarterly installments, from the date of Dr. von Moltke’s appointment to the Board.

 

The Company expects to enter into its standard indemnification agreement for directors with Dr. von Moltke, the form of which was previously filed by the Company as Exhibit 10.1 to the Company’s Registration Statement on Form S-1 (File No. 333-192230), filed with the Securities and Exchange Commission on January 17, 2014.

 

Item 7.01Regulation FD Disclosure.

 

On November 3, 2022, the Company issued a press release announcing the appointment of Dr. von Moltke to the Board. A copy of the press release is being furnished to the SEC as Exhibit 99.1 to this Form 8-K and is incorporated by reference to this Item 7.01.

 

The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any of the Company’s filings with the SEC under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such a filing.

 

Item 9.01Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.    
99.1   Press Release dated November 3, 2022
104   Cover page interactive data file (formatted as Inline XBRL)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CARA THERAPEUTICS, INC.
   
  By: /s/ CHRISTOPHER POSNER
    Christopher Posner
    Chief Executive Officer

 

Date: November 3, 2022

 

 

 

 EX-99.1 2 tm2229601d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

Cara Therapeutics Announces Appointment of Lisa von Moltke, M.D., to its Board of Directors

 

STAMFORD, Conn., November 3, 2022 – Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Lisa von Moltke, M.D., to its Board of Directors. Dr. von Moltke currently serves as Executive Vice President and Chief Medical Officer at Seres Therapeutics, Inc.

 

“We are very pleased to welcome Lisa to our board of directors,” said Christopher Posner, President, Chief Executive Officer and Director of Cara Therapeutics. “Her extensive clinical development and pharmacology expertise will be of great value as we continue executing our strategy to expand the utility and maximize the potential of oral difelikefalin for the treatment of pruritus.”

 

“It’s an exciting time to be joining the board of Cara Therapeutics,” said Dr. von Moltke. “I look forward to working with the Cara team as its late-stage oral difelikefalin pipeline progresses in multiple therapeutic indications for the treatment of pruritus, an underserved and burdensome condition.”

 

Dr. von Moltke has directed successful development programs, led clinical teams, and interacted with regulatory agencies across multiple therapeutic areas. Prior to joining Seres, Dr. von Moltke served in roles of increasing seniority at Alkermes, Inc., culminating as Senior Vice President and Head of Clinical Development. Previously, Dr. von Moltke was Vice President Clinical Pharmacology at Sanofi/Genzyme Corporation, where she also served as U.S. Head Clinical & Exploratory Pharmacology Sciences (CEP) and Early Development and later as Head CEP for Japan and China regions. Earlier in her career, she was Head, Translational Medicine for the Takeda Oncology Company. Dr. von Moltke has served as President of the American College of Clinical Pharmacology and Editor-in-Chief of The Journal of Clinical Pharmacology. She received a B.A. from Wellesley College and M.D. from Michigan State University, College of Human Medicine.

 

About Cara Therapeutics

 

Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. The Company has completed a Phase 2 proof-of-concept trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica. A Phase 2 proof-of-concept trial in primary biliary cholangitis patients with moderate-to-severe pruritus is ongoing. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.

 

 

 

 

 

 

Forward-looking Statements

 

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements include statements concerning the Company’s future development of oral difelikefalin for treatment of pruritus. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in the Company’s filings with the Securities and Exchange Commission, including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 and its other documents subsequently filed with or furnished to the Securities and Exchange Commission, including its Form 10-Q for the quarter ended September 30, 2022. All forward-looking statements contained in this press release speak only as of the date on which they were made. Cara Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

 

MEDIA CONTACT:

Annie Spinetta

6 Degrees

973-768-2170

aspinetta@6degreespr.com

 

INVESTOR CONTACT:

Iris Francesconi, Ph.D.

Cara Therapeutics

203-406-3700

investor@caratherapeutics.com

 

 

 

 EX-101.SCH 3 cara-20221101.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 cara-20221101_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 cara-20221101_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2229601d1_ex99-1img01.jpg GRAPHIC begin 644 tm2229601d1_ex99-1img01.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover
Nov. 01, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 01, 2022
Entity File Number 001-36279
Entity Registrant Name CARA THERAPEUTICS, INC.
Entity Central Index Key 0001346830
Entity Tax Identification Number 75-3175693
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 4 Stamford Plaza
Entity Address, Address Line Two 107 Elm Street
Entity Address, Address Line Three 9th Floor
Entity Address, City or Town Stamford
Entity Address, State or Province CT
Entity Address, Postal Zip Code 06902
City Area Code 203
Local Phone Number 406-3700
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol CARA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 tm2229601d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001346830 2022-11-01 2022-11-01 iso4217:USD shares iso4217:USD shares 0001346830 false 8-K 2022-11-01 CARA THERAPEUTICS, INC. DE 001-36279 75-3175693 4 Stamford Plaza 107 Elm Street 9th Floor Stamford CT 06902 203 406-3700 false false false false Common Stock, par value $0.001 per share CARA NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://caratherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2229601d1_8k.htm cara-20221101.xsd cara-20221101_lab.xml cara-20221101_pre.xml tm2229601d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2229601d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm2229601d1_8k.htm" ] }, "labelLink": { "local": [ "cara-20221101_lab.xml" ] }, "presentationLink": { "local": [ "cara-20221101_pre.xml" ] }, "schema": { "local": [ "cara-20221101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "CARA", "nsuri": "http://caratherapeutics.com/20221101", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2229601d1_8k.htm", "contextRef": "From2022-11-01to2022-11-01", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://caratherapeutics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2229601d1_8k.htm", "contextRef": "From2022-11-01to2022-11-01", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001104659-22-114206-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-114206-xbrl.zip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end